3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
暂无分享,去创建一个
Young Hye Kim | Rudolph E Tanzi | R. Tanzi | Doo Yeon Kim | Young Hye Kim | Se Hoon Choi | L. Quinti | Luisa Quinti
[1] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[2] Basavaraj Hooli,et al. A three-dimensional human neural cell culture model of Alzheimer’s disease , 2014, Nature.
[3] Hiroyuki Miyoshi,et al. Self-formation of functional adenohypophysis in three-dimensional culture , 2011, Nature.
[4] T. Bayer,et al. Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice , 2003, Experimental Neurology.
[5] N. Kotov,et al. Three-dimensional cell culture matrices: state of the art. , 2008, Tissue engineering. Part B, Reviews.
[6] B. de Strooper,et al. Loss‐of‐function presenilin mutations in Alzheimer disease , 2007, EMBO reports.
[7] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[8] G. Glenner,et al. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.
[9] L. Tsai,et al. Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer’s Disease Phenotypes , 2016, PloS one.
[10] J. Weuve,et al. 2016 Alzheimer's disease facts and figures , 2016 .
[11] M. Frech,et al. Differentiation of Human Neural Progenitor Cells in Functionalized Hydrogel Matrices , 2012, BioResearch open access.
[12] Young Hye Kim,et al. A 3D human neural cell culture system for modeling Alzheimer's disease , 2015, Nature Protocols.
[13] D. Nicholson,et al. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease , 2016, Acta Neuropathologica.
[14] N. Cutler,et al. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[15] J. Fisher,et al. Neural differentiation of pluripotent cells in 3D alginate-based cultures. , 2014, Biomaterials.
[16] Young Hye Kim,et al. Alzheimer's in 3D culture: Challenges and perspectives , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.
[17] R. J. Kelleher,et al. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.
[18] A. Dinnyés,et al. Establishment of PSEN1 mutant induced pluripotent stem cell (iPSC) line from an Alzheimer's disease (AD) female patient. , 2016, Stem cell research.
[19] G. Schellenberg,et al. Regulation of tau isoform expression and dementia. , 2005, Biochimica et biophysica acta.
[20] Michelle C. LaPlaca,et al. Three-Dimensional Neuronal Cultures , 2010 .
[21] Ronan M. T. Fleming,et al. Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. , 2015, Lab on a chip.
[22] B. Strooper,et al. Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.
[23] J. Mertens,et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. , 2012, The American journal of pathology.
[24] J. Götz,et al. Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.
[25] Han-Kyu Lee,et al. Three Dimensional Human Neuro-Spheroid Model of Alzheimer’s Disease Based on Differentiated Induced Pluripotent Stem Cells , 2016, PloS one.
[26] Kristopher L. Nazor,et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.
[27] R. Shigemoto,et al. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology , 2003, Neuroscience Letters.
[28] M. Araúzo-Bravo,et al. Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein , 2015, Stem cell reports.
[29] D. Selkoe,et al. The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. , 2014, Human molecular genetics.
[30] M. Spillantini,et al. Frontotemporal Dementia with Tau Pathology , 2007, Neurodegenerative Diseases.
[31] J. C. Love,et al. Single-Cell Detection of Secreted Aβ and sAPPα from Human IPSC-Derived Neurons and Astrocytes , 2016, The Journal of Neuroscience.
[32] K. Duff,et al. Progress in the modeling of neurodegenerative diseases in transgenic mice , 2001, Current opinion in neurology.
[33] Kun Zhang,et al. The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. , 2013, Cell reports.
[34] A. Kriegstein,et al. Cerebral Organoids in a Dish: Progress and Prospects , 2013, Cell.
[35] Colin J. Mahoney,et al. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT , 2015, Human molecular genetics.
[36] R. Tanzi,et al. Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications. , 2015, US neurology.
[37] David L Kaplan,et al. Bioengineered functional brain-like cortical tissue , 2014, Proceedings of the National Academy of Sciences.
[38] P. Adlard,et al. Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging , 2009, Neurobiology of Aging.
[39] S. Itohara,et al. Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.
[40] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[41] Ben A. Barres,et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.
[42] D. Selkoe. Alzheimer's Disease Is a Synaptic Failure , 2002, Science.
[43] Jean-Louis Viovy,et al. A review of microfabrication and hydrogel engineering for micro-organs on chips. , 2014, Biomaterials.
[44] R. Livesey. A human stem cell model of early Alzheimer's disease pathology in Down syndrome , 2012, Alzheimer's & Dementia.
[45] J. Thomson,et al. Human Induced Pluripotent Stem Cell Derived Neuronal Cells Cultured on Chemically-Defined Hydrogels for Sensitive In Vitro Detection of Botulinum Neurotoxin , 2015, Scientific Reports.
[46] A. Levey,et al. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities , 2007, The EMBO journal.
[47] F. Edwards,et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines , 2007, BMC Neuroscience.
[48] K. Blennow,et al. APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons , 2015, Cell reports.
[49] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[50] B. Strooper,et al. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.
[51] M. Frech,et al. Effect of 3D-scaffold formation on differentiation and survival in human neural progenitor cells , 2010, Biomedical engineering online.
[52] R. Vassar,et al. Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease , 2016, Neuroscience & Biobehavioral Reviews.
[53] R. Yan. Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs , 2016, Translational Neurodegeneration.
[54] Jianping Fu,et al. On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology. , 2015, Biomaterials.
[55] Roger D. Kamm,et al. Modeling the Blood-Brain Barrier in a 3D triple co-culture microfluidic system , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).
[56] A. Dinnyés,et al. Establishment of induced pluripotent stem cell (iPSC) line from an 84-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.
[57] Arthur W. Toga,et al. Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.
[58] Ottavio Arancio,et al. Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors , 2014, PloS one.
[59] I. Lombardo,et al. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.
[60] L. Liotta,et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.
[61] Bradley T. Hyman,et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.
[62] R. Vassar. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.
[63] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[64] Y. Uchida,et al. The role of calsyntenin‐3 in dystrophic neurite formation in Alzheimer's disease brain , 2016, Geriatrics & gerontology international.
[65] J. Kessler,et al. Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death , 2014, Molecular Neurodegeneration.
[66] Qinying Wang,et al. Direct Conversion of Normal and Alzheimer's Disease Human Fibroblasts into Neuronal Cells by Small Molecules. , 2015, Cell Stem Cell.
[67] J. Schneider,et al. Central role for PICALM in amyloid–β blood–brain barrier transcytosis and clearance , 2015, Nature Neuroscience.
[68] J. Trojanowski,et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.
[69] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[70] J. Trojanowski,et al. The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.
[71] Matthew Trotter,et al. Capture of Neuroepithelial-Like Stem Cells from Pluripotent Stem Cells Provides a Versatile System for In Vitro Production of Human Neurons , 2012, PloS one.
[72] X. Zhu,et al. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer’s disease , 2015, Molecular Psychiatry.
[73] R. Armstrong. A critical analysis of the 'amyloid cascade hypothesis'. , 2014, Folia neuropathologica.
[74] P. Whitehouse,et al. Alteration of neuritic cytoarchitecture in Alzheimer disease. , 1989, Progress in clinical and biological research.
[75] Madeline A. Lancaster,et al. Cerebral organoids model human brain development and microcephaly , 2013, Nature.
[76] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[77] H. Okano,et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. , 2011, Human molecular genetics.
[78] James Adjaye,et al. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks , 2015, BMC Genomics.
[79] Antonia Gutierrez,et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus , 2011, Acta Neuropathologica.
[80] Daniel J. Gaffney,et al. Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations , 2015, Brain : a journal of neurology.
[81] A. Dinnyés,et al. Establishment of induced pluripotent stem cell (iPSC) line from a 75-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.
[82] A. Dinnyés,et al. Establishment of induced pluripotent stem cell (iPSC) line from a 63-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.
[83] K. Ando,et al. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. , 2011, The American journal of pathology.
[84] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[85] Rudolph E. Tanzi,et al. Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. , 2014, JAMA neurology.
[86] B. de Strooper,et al. The amyloid cascade hypothesis: are we poised for success or failure? , 2016, Journal of neurochemistry.
[87] John Q Trojanowski,et al. The role of tau in Alzheimer's disease. , 2002, The Medical clinics of North America.
[88] R. Tanzi. A brief history of Alzheimer's disease gene discovery. , 2012, Journal of Alzheimer's disease : JAD.
[89] Marc Tessier-Lavigne,et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9 , 2016, Nature.
[90] G. Waldemar,et al. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1. , 2016, Stem cell research.
[91] J. Chin,et al. Selecting a mouse model of Alzheimer's disease. , 2010, Methods in molecular biology.
[92] G. Lajoie,et al. Matrigel: A complex protein mixture required for optimal growth of cell culture , 2010, Proteomics.
[93] Fei Liu,et al. Tau in Alzheimer disease and related tauopathies. , 2010, Current Alzheimer research.
[94] Han-Kyu Lee,et al. Lab resource : stem cell line Peripheral blood mononuclear cell-converted induced pluripotent stem cells ( iPSCs ) from an early onset Alzheimer ' s patient , 2016 .
[95] Anna Ochałek,et al. Establishment of induced pluripotent stem cell (iPSC) line from a 57-year old patient with sporadic Alzheimer's disease. , 2016, Stem cell research.
[96] Padma Gopalan,et al. Surface functionalization and dynamics of polymeric cell culture substrates. , 2016, Current opinion in biotechnology.
[97] Christopher M Ward,et al. Familial Alzheimer's disease modelling using induced pluripotent stem cell technology. , 2014, World journal of stem cells.
[98] R. Tanzi,et al. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.
[99] G. Sethuraman,et al. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings , 2014, Current medical research and opinion.
[100] Katsuhiro Yoshikawa,et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. , 2013, Cell stem cell.
[101] Jing Zhao,et al. Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells , 2015, Molecular Neurodegeneration.
[102] Nic D. Leipzig,et al. 3D Differentiation of Neural Stem Cells in Macroporous Photopolymerizable Hydrogel Scaffolds , 2012, PloS one.
[103] J. Trojanowski,et al. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. , 2011, Cold Spring Harbor perspectives in medicine.